content

Ray Therapeutics and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership

Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, a gene therapy-focused contract development and...

IQVIA selected to accelerate clinical development of VYVGART by argenx SE

IQVIA announced an agreement today with argenx SE. The multi-year contract covers a unique collaboration for the development of new indications for VYVGARTโ„ข (efgartigimod...

AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio

AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access...

Element Partners with Interpretation Expert Genoox to Validate the AVITI System for the RUGD Application

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with Genoox, a community-driven genomic data platform, to demonstrate...

IDT Biologika Collaborates with Exothera to Push Forward the Scale-Up of Viral Vaccines

IDT Biologika, a leading Contract Development and Manufacturing Organization (CDMO) specialized in vaccines, gene and immune therapy and oncolytic viruses, and Exothera S.A. collaborate...

CTI Biopharma’s Drug For Bone Marrow Cancer Approved By FDA

The U.S. Food and Medication Administration authorised CTI BioPharma Corp's drug for treating adult patients with a kind of bone marrow cancer who also...

Thermo Fisher Scientific Continues Collaboration to Support Biopharmaceutical Discovery and Development

Thermo Fisher Scientific, the world leader in serving science, and Symphogen, an affiliate of and the antibody center of excellence within the international pharmaceutical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read